Conference
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM)
Abstract
15506
Background: Sorafenib (SOR) was demonstrated to be safe and effective in a phase III trial of previously treated RCC pts; however, pts with BM were excluded. BM occur in 5–10% of RCC pts, and generally portend a poor prognosis. Safety and efficacy of SOR in this pt population was therefore explored in a subset analysis of ARCCS, a community-based expanded access program. Methods: Pts received SOR 400 mg bid in this …
Authors
Henderson CA; Bukowski RM; Stadler WM; Dutcher JP; Kindwall-Keller T; Hotte SJ; Logie K; Baltz B; Wilson K; Figlin RA
Volume
25
Pagination
pp. 15506-15506
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 20, 2007
DOI
10.1200/jco.2007.25.18_suppl.15506
Conference proceedings
Journal of Clinical Oncology
Issue
18_suppl
ISSN
0732-183X